Last updated on May 2017

Immune Monitoring Protocol in Men With Prostate Cancer Enrolled in a Clinical Trial of Sipuleucel-T


Brief description of study

The purpose of this study is to evaluate the immune response induced by sipuleucel-T (Provenge®).

Detailed Study Description

Subjects will receive sipuleucel-T, and potentially other medications, as part of the clinical trial in which they are concurrently enrolled. For this study, cellular and humoral immune responses will be assessed. No additional study treatments will be conducted beyond what is required for the subject's concurrent clinical trial.

Clinical Study Identifier: NCT01727154

Find a site near you

Start Over

Cancer Center of Kansas

Wichita, KS United States
  Connect »

First Urology, PSC

Jeffersonville, IN United States
  Connect »

21st Century Oncology

Scottsdale, AZ United States
  Connect »

Prostate Oncology Specialists, Inc.

Marina del Rey, CA United States
  Connect »

Howard University Cancer Center

Washington, D.C., United States
  Connect »

21st Century Oncology

Fort Myers, FL United States
  Connect »

Georgia Urology, P.A.

Marietta, GA United States
  Connect »

Tulane University

New Orleans, LA United States
  Connect »

Highland Clinic

Shreveport, LA United States
  Connect »

Tufts Medical Center

Boston, MA United States
  Connect »

Henry Ford Health System

Detroit, MI United States
  Connect »

St. Louis Cancer Care, LLP

Bridgeton, MO United States
  Connect »

St. Louis Cancer Care, LLP

Saint Louis, MO United States
  Connect »

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.